Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of reinstating the annual health check target of 75% for people with learning disabilities.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department and NHS England have not undertaken a specific assessment of reinstating the 75% annual health check target for people with a learning disability. My Rt Hon. Friend, the Secretary of State for Health and Social Care, wrote to general practitioners (GPs) in October 2025 emphasising the importance of the learning disability register and providing high quality annual health checks. These checks are the first line of defence for people with a learning disability, many of whom live with additional health needs, including long-term conditions. Strong support from GPs to maintain learning disability annual health checks has enabled more people than ever before to receive a health check and health action plan, an increase of more than 20% since 2020.
As of March 2025, 81.5% of eligible people on the GP learning disability register received an annual health check, surpassing the previous 75% National Health Service target.
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has undertaken of the potential impact of Medicines and Healthcare products Regulatory Agency winter wellness campaigns during the last five years.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The main Government health winter campaigns are run by the UK Health Security Agency and NHS England, which the Medicines and Healthcare products Regulatory Agency (MHRA) supports.
The MHRA also runs annual winter campaigns to raise public awareness of medicines and medical devices safety that achieves media coverage and social media engagement.
For example, the MHRA’s 2025/26 campaign provided five public safety tips covering medicines and medical devices. It achieved media coverage in national print and online, regional and trade press, as well as an interview on BBC One Breakfast.
The MHRA created and posted social media content throughout this period which was seen approximately 50,000 times. The MHRA also worked with key stakeholders, such as the National Fire Chiefs Council, to help amplify safety messages.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the feasibility of establishing a dedicated, no-fault compensation scheme for individuals harmed by sodium valproate exposure, in the context of the recommendations of the Independent Medicines and Medical Devices Safety Review (2020).
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not yet undertaken an assessment of the feasibility of establishing a dedicated, no-fault compensation scheme for individuals harmed by sodium valproate exposure, in the context of the recommendations of the Independent Medicines and Medical Devices Safety Review (IMMDS).
The previous administration accepted seven of the nine recommendations of the IMMDS Review, whether in full, in part, or in principle, including issuing an unreserved apology on behalf of the healthcare system, appointing Dr Henrietta Hughes as the first Patient Safety Commissioner for England, and establishing nine specialist mesh centres now operating across the country.
This is a complex, cross-Government policy area involving multiple organisations. As set out in the Hughes Report, the Government is carefully considering the Patient Safety Commissioner’s recommendations, including the proposed approaches to redress for those harmed by sodium valproate. This work requires coordinated input from several departments, and we will provide a further update in due course.
I met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and made clear that the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders.
Asked by: Mohammad Yasin (Labour - Bedford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department recognises problem debt as a public health issue; and what support the NHS and social care services provide to people with problem debt.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Research shows that there is a link between health and financial health with a large amount of people who experience mental health problems also struggling with their finances.
NHS Talking Therapies has recently collaborated with the Money and Pensions Service to promote the Money Guiders programme that helps equip mental health practitioners to have money conversations with their patients. In addition, each NHS Talking Therapies service has embedded employment advisors who provide a non-clinical support service to help patients using Talking Therapies to address work-related issues, offering practical support and solutions for any work barriers which can include unemployment and returning to work.
The Individual Placement and Support is a well‑evidenced, National Institute for Health and Care Excellence‑approved employment programme, funded by NHS England, that offers intensive, individually tailored support to get people into work, with ongoing support for the employer and employee to help ensure the person keeps their job.
Individuals may also be able to access the Breathing Space Scheme, which was set up to encourage more people in problem debt to access professional debt advice. A standard breathing space provides a 60-day period of protection by pausing creditor enforcement action and most interest, fees, and charges. Given the link between problem debt and mental health difficulties, the Mental Health Crisis Breathing Space was also established for individuals who are receiving mental health crisis treatment.
Where debt is the result of gambling addiction, individuals can access their local National Health Service gambling service via self- or professional referral.
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to raise public awareness of the risks of taking multiple doses of different over-the-counter medicines which contain the same active ingredient.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department with responsibility for ensuring medicines meet appropriate standards of quality, efficacy, and safety. The Human Medicines Regulations 2012 lays out the conditions of the licencing and marketing of a medicine. This includes the information which must be provided with the medicinal product.
Schedule 24 specifies that the outer and immediate packaging of medicinal products must display the name of the medicinal product, the strength and pharmaceutical form, and when the product contains more than three active substances, the common name for the active substances. In addition, regulation 259 states that packaging or outer label should present the name in braille for the blind or partially sighted. In addition, schedule 24 states that the labelling should display the contents, for instance the number of tablets, where to store, expiry date, the manufacturers name, and any special precautions relating to the product.
The MHRA has recently updated voluntary Best Practice Guidance on the general sale of medicines for pain, to further highlight the risks of overdose, to address public concerns and recognise current sales techniques. Links are also provided to patient support groups, including Papyrus for young people. The update was undertaken in collaboration with retailers, stakeholders and healthcare professionals, and the updated guidance is avaiable at the following link:
Most retailers adhere to the guidelines on not promoting multiple purchases and have introduced in store measures such as till bars that restrict sales to a maximum of two packs across a range of products containing aspirin, paracetamol, or ibuprofen. The aim of these voluntary measures is to balance the need of people for access to pain relief medicines against the dangers for vulnerable individuals and to reduce the opportunity for customers to purchase on impulse excessive quantities of any single analgesic, like paracetamol, aspirin, or ibuprofen.
Paracetamol and ibuprofen are well-known medicines for pain, which when taken as recommended, have well-established safety profiles. The vast majority of patients use these medicines responsibly as effective pain-relievers.
The use of paracetamol and accidental overdose is a safety concern, especially in relation to the many trade names of non-prescription and prescription medicines containing paracetamol. Therefore, the Human Medicines Regulations 2012 contain a number of conditions for the presentation of these medicines to highlight the presence of paracetamol in a medicine.
Schedule 25, Part 4 of the Human Medicines Regulations sets out statutory labelling requirements for paracetamol medicines to highlight the presence of paracetamol in that product. Paragraph 14 states that, except where the name of the product includes the word “paracetamol” and appears on the outer and immediate packaging, the words “contains paracetamol” should be displayed.
Paragraph 15 states that the labelling must highlight paracetamol on the front face of the carton or label and should also contain the warning: “Do not take more medicine than the label tells you to. If you do not get better, talk to your doctor”, which must appear adjacent to either the directions for use or the recommended dosage.
Further to this, if the product contains a leaflet, paragraph 16 states that if the product contains paracetamol, unless the product is wholly or mainly intended for children aged 12 years old or younger, the words “Do not take anything else containing paracetamol while taking this medicine” and the warning “Talk to a doctor at once if you take too much of this medicine, even if you feel well” must be included. If the product does not contain a leaflet, then the words “Talk to a doctor at once if you take too much of this medicine, even if you feel well. This is because too much paracetamol can cause delayed, serious liver damage” should be displayed.
Schedule 8 of the regulations also set out the material which must accompany any application for the marketing of a medicine. The Summary of Product Characteristics (SmPC) as referenced in part 2, for healthcare professionals, provides a summary of the clinical particulars in the use of a medicine, including the recommended maximum daily dose. In addition, particulars in reference to overdose are provided. This includes the potential dose over which liver damage may occur and potential risk factors which may elevate the risk of overdose, including medical history, concomitant medicines, or alcohol intake. A summary of the symptoms of overdose and management are also provided.
The market authorisation holders are obligated under the Human Medicines Regulations to continually review the safety of their medicines and to inform the MHRA of any serious adverse reactions. The MHRA continues to monitor the safety of all medicines and if necessary, will take advice from our independent experts on recommended regulatory action. The MHRA provides a list of the SmPCs and patient leaflets for all medicines at the following link:
Additional resources on product information and the treatment of overdose are available from the British National Formulary (BNF), the electronic medicines compendium, the National Poisons Information Service, and National Health Service, with further information available at the following link:
https://www.nhs.uk/medicines/paracetamol-for-adults/
The Human Medicines Regulations and the BNF highlight the information that is required in general and electronic prescriptions.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether interim compensation payments have been considered for families involved in the first ten claims of the FAC litigation concerning sodium valproate.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not specifically considered interim compensation for the families involved in the Fetal Anti‑Convulsant litigation. On redress more broadly, I met with the Patient Safety Commissioner in December 2025, to discuss progress on the Hughes Report and made clear that the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders.
This is a complex, cross‑Government policy area involving multiple organisations. As set out in the Hughes Report, the Government is carefully considering the Patient Safety Commissioner’s recommendations, including the proposed approaches to redress for those harmed by sodium valproate. This work requires coordinated input from several departments, and we will provide a further update in due course.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure that people with learning disabilities do not remain in hospital beds when there is no medical need for them to do so.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Our 10-Year Health Plan sets out to tackle health inequalities and offer people more holistic, on-going support in the community. It is important that people are discharged promptly from hospital with the right support, both for their outcomes, and to free up beds for other patients.
The Department is working to ensure that patients, including people with a learning disability, can leave hospital promptly by strengthening access to appropriate community-based services. Local systems, supported through the £9 billion Better Care Fund, are required to plan jointly for integrated health and social care that supports individuals to live independently. This includes commissioning supported living arrangements, residential care where needed, and tailored packages of domiciliary care.
For 2025/26, National Health Service trusts have been asked to focus on eliminating discharge delays of more than 48 hours caused by issues within acute hospitals, and to work with local authorities on eliminate the longest delays, starting with those of over 21 days.
NHS Operational Planning Guidance also sets an objective to deliver a minimum 10% reduction in the use of mental health inpatient care for people with a learning disability and autistic people in 2025/26. The NHS Medium-Term Planning Framework maintains this focus, with an ambition for a 10% year-on-year reduction up to 2028/29.
Asked by: Mark Pritchard (Conservative - The Wrekin)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what advice and support his Department is providing to people in Shropshire who claim they have contracted, or might develop, serious illnesses as a result of using Johnson & Johnson talcum powder products.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Individuals in Shropshire who believe they may have been affected by use of talcum products should seek medical advice from their general practitioner. They may also wish to consider contacting specialist organisations for support and information on legal action.
The Medicine and Healthcare products Regulatory Agency (MHRA) is the Government agency responsible for ensuring that medicines and medical devices work and are acceptably safe. Additives in medicines, termed excipients, are required to comply with the standards laid down in pharmacopeial monographs and can only be included in medicinal products at levels that are considered to be safe.
The MHRA is aware of general concerns in relation to the presence of asbestos in commercial talcum powder. However, pharmaceutical grade talcum powder has strict controls on the presence of asbestos. The British Pharmacopeia monograph for Purified Talc states that “Talc derived from deposits that are known to contain associated asbestos is not suitable for pharmaceutical use”. Furthermore, testing is required to confirm the absence of asbestos.
Oversight of commercial talc powder, including advice and support, falls within the remit of the Department for Business and Trade and specifically the Office of Product Safety and Standards (OPSS). The OPSS is the regulator of product safety and seeks to ensure that manufacturers, importers, and all those in the supply chain take steps to ensure that consumer products are safe, and they take any reports of negative health outcomes related to products incredibly seriously. Any serious undesirable effects related to cosmetic products should be directly reported to OPSS, to ensure that they can take the correct action. If a consumer wishes to report a serious undesirable effect, OPSS recommend contacting Trading Standards who can support with the process.
Asked by: Matt Vickers (Conservative - Stockton West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent progress he has made in improving access to kidney transplantation, including reducing waiting times and increasing rates of living and deceased organ donation.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS Blood and Transplant (NHSBT) is the organisation responsible for organ donation services in the United Kingdom. Figures on the number of patients active on the kidney transplant waiting list and median waiting times are available at the following link:
https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/36811/section-5-kidney-activity.pdf
The Department, along with NHSBT, continues to take action to improve access to kidney transplantation. This includes high profile, year-round campaigns including Living Donation Week, Organ Donation Week, and World Kidney Day, and partnerships with charities and community groups to promote living donation, the UK Living Kidney Sharing Scheme (UKLKSS) and the importance of declaring wishes on the Organ Donation Register (ODR). In addition, the Living Donor Futures programme, launching this early this year, will look at how NHSBT can support the growth of living donor programmes locally and within the UKLKSS. Further information on the UKLKSS is available at the following link:
https://www.odt.nhs.uk/living-donation/uk-living-kidney-sharing-scheme/;
The Department-led Implementation Steering Group for Organ Utilisation is working to maximise the potential for organ transplantation, aiming to reduce waiting times and improve access. This includes the initiation of a national programme of Assessment and Recovery Centres (ARCs) by NHSBT, which will utilise innovation to enhance the assessment, evaluation, and utilisation of donor organs. Pilot ARCs are set to begin in early 2026. Further information on the Implementation Steering Group for Organ Utilisation is available at the following link:
https://www.odt.nhs.uk/odt-structures-and-standards/clinical-leadership/implementation-steering-group-for-organ-utilisation/
Additionally, the Organ Donation Joint Working Group recently published recommendations to improve organ donation consent rates, increase societal action for organ donation, and increase the pool of potential donors in their report this January. The recommendations are available at the following link:
https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/38066/odjwg-report.pdf
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the Medicines and Healthcare products Regulatory Agency plans to update its public communications strategy to increase the reporting of adverse reactions to medical supplements.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare Products Regulatory Agency (MHRA) is an executive agency of the Department and regulates medicines, for human use, medical devices, and blood components for transfusion in the United Kingdom.
If a “medical supplement” was covered by the definition of a medicinal product as set out in the Human Medicines Regulations 2012, or the definition of a medical device under Medical Devices Regulations, it would fall under the remit of the MHRA and would be subject to the relevant regulatory requirements. Food supplements are regulated by the Food Standards Agency.
Ongoing efforts to raise awareness of the Yellow Card scheme will enhance public understanding of the scheme’s remit and the range of healthcare products it covers, including the reporting of suspected side effects associated with herbal and/or homeopathic medicines, as set out in existing information and general awareness materials available on the Yellow Card scheme website.